Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Domesco Medical Import Export JSCSTC:DMC 79 3-Year EBITDA Growth Rate is 1.70% as of Jun. 2026, which is 71% below its 10-year median of 5.80. GuruFocus rates STC:DMC with a GF Score™ of 79/100 and a GF Value™ of ₫68,371.89 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 810 Drug Manufacturers companies, Domesco Medical Import Export JSC ranks worse than 63.46% on this metric.
During the past 12 months, Domesco Medical Import Export JSC's average EBITDA Per Share Growth Rate was 19.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 1.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 3.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 0.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Domesco Medical Import Export JSC was 14.80% per year. The lowest was -12.60% per year. And the median was 5.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Domesco Medical Import Export JSC 3-Year EBITDA Growth Rate Related Terms
STC:DMC vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Domesco Medical Import Export JSC's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Domesco Medical Import Export JSC 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Domesco Medical Import Export JSC's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Domesco Medical Import Export JSC's 3-Year EBITDA Growth Rate falls into.
Domesco Medical Import Export JSC 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 1.70% mean?
Domesco Medical Import Export JSC (STC:DMC) has a 3-Year EBITDA Growth Rate of 1.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Domesco Medical Import Export JSC and its competitors. This is 71% below median its historical median of 5.80. According to the industry distribution chart, Domesco Medical Import Export JSC ranks #514 out of 810 companies in the Drug Manufacturers industry, placing it in the top 63.5%.
Is Domesco Medical Import Export JSC's 3-Year EBITDA Growth Rate too high?
Domesco Medical Import Export JSC's current 3-Year EBITDA Growth Rate of 1.70% is 71% below median its 10-year median of 5.80. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.85. Domesco Medical Import Export JSC's value of 1.70% is 80.8% below this industry median. Based on the distribution chart, Domesco Medical Import Export JSC ranks #514 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Domesco Medical Import Export JSC has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Domesco Medical Import Export JSC's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Domesco Medical Import Export JSC ranks #514 out of 810 companies for 3-Year EBITDA Growth Rate. This places Domesco Medical Import Export JSC in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.85. Domesco Medical Import Export JSC's value of 1.70% is 80.8% below this benchmark. While the company's 10-year median is 5.80 vs. the industry median of 8.85, Domesco Medical Import Export JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.85, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Domesco Medical Import Export JSC's current 3-Year EBITDA Growth Rate of 1.70% is 80.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Domesco Medical Import Export JSC and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Domesco Medical Import Export JSC's current 3-Year EBITDA Growth Rate is 1.70%, which is 71% below median its own 10-year median of 5.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Domesco Medical Import Export JSC stock overvalued right now?
Based on GuruFocus' analysis, Domesco Medical Import Export JSC (STC:DMC) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫68,371.89, compared to a current price of ₫58,000.00 — trading 15.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 1.70%, which is 71% below median its 10-year median of 5.80 and 80.8% below the Drug Manufacturers industry median of 8.85. Domesco Medical Import Export JSC's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Domesco Medical Import Export JSC (STC:DMC), the current 3-Year EBITDA Growth Rate is 1.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Domesco Medical Import Export JSC (STC:DMC) Overvalued in 2026?
Based on GuruFocus' analysis, Domesco Medical Import Export JSC stock appears to be undervalued.
The current stock price of ₫58,000.00 is trading 15.2% below its estimated GF Value™ of ₫68,371.89.
GuruFocus considers Domesco Medical Import Export JSC to be Modestly Undervalued.
Key valuation signals for STC:DMC:
3-Year EBITDA Growth Rate: 1.70% (71% below median its 10-year median of 5.80)
GF Value™: ₫68,371.89 vs. price of ₫58,000.00 (15.2% below fair value)
Industry Position: 80.8% below the Drug Manufacturers median (#514 of 810)
No single metric tells the full story. See the STC:DMC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Domesco Medical Import Export JSC is specialized in research, development, production, marketing and trading of Pharmaceuticals, medicines derived from Pharmaceutical materials, functional food, pure drinking water and medical beverages. It operates in import and export of medicines, medicine materials, food - functional foods, medical supplies, and medical equipment for medical examination and treatment for the whole people.
79GF Score
Get the complete analysis for STC:DMC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DMC has been successfully added to your 
